SciELO - Scientific Electronic Library Online

 
vol.24 número5Complicaciones mecánicas del infarto agudo de miocardio: aunque infrecuentes, potencialmente letalesArritmias ventriculares como manifestación de índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Colombiana de Cardiología

versión impresa ISSN 0120-5633

Resumen

DUQUE, Mauricio; GAVIRIA, María C.; GONZALEZ, Juanita  y  GALLO, Juan E.. con anti-PCSK9 Heterozygous familial hypercholesterolaemia being managed with anti-PCSK9. Rev. Colomb. Cardiol. [online]. 2017, vol.24, n.5, pp.510-510.  Epub 27-Jun-2017. ISSN 0120-5633.  http://dx.doi.org/10.1016/j.rccar.2017.03.002.

Introduction:

Familial hypercholesterolaemia is a substantial risk factor for suffering premature coronary, peripheral arterial, and valular disease. There are two forms described, depending on their genetics and zygosity, as well as three associated genetic mutations. Although treatment with statins is considered first line, some patients do not reach targets, as such that that PCSK9 inhibitors have been used as a new strategy.

Materials and method:

A case is presented of a 42 year-old patient with heterozygous familial hypercholesterolaemia treated with PCSK9 inhibitors. The criteria and genetic studies used to make a diagnosis are described, as well as the chronology of the treatments that have been received and the laboratory results before and after starting with evolocumab. A review has also been made of the subject of familial hypercholesterolaemia and its treatment with PCSK9 inhibitors.

Conclusions:

Familial hypercholesterolaemia is a diseases that may have serious cardiovascular consequences. PCSK9 inhibitors have become a promising alternative for those who do not respond to conventional therapies. Studies are required that can corroborate or contradict the benefits and adverse effects found up until now in patients subjected to these new therapies in order to offer an ideal and appropriate treatment.

Palabras clave : Familial hypercholesterolaemia; Cardiovascular disease; Coronary disease; Inhibitors.

        · resumen en Español     · texto en Español     · Español ( pdf )